Co-Founder, Chairman and Chief Executive Officer
Derek Proudian is a Silicon Valley venture investor, start-up CEO, and entrepreneur.
He has served as the CEO of six venture-capital backed companies, including Zip2 (Elon Musk’s first company, which he sold to Compaq for over $300 million). Mr. Proudian has worked as a general partner at the venture capital firm Mohr Davidow Ventures (MDV), a venture partner at Morgan Stanley Ventures, and as an R&D manager at Hewlett-Packard Labs. As a general partner at MDV he was part of a team credited with delivering $3.5 billion in returns to limited partners from an initial $225 million investment.
As a founding board member, Mr. Proudian has helped shepherd a number of companies to successful exits, including: mSpot, which was sold to Samsung in 2012 for $50 million; Daintree Networks, which was sold to General Electric in 2016 for $100 million; SquareTrade, which was sold to Allstate in January 2017 for $1.4 billion; and Newtrax Technologies, which was sold to Sandvik AB in June 2019 for $70 million.
He received a BS in Cognitive Science, a BA in Creative Writing, an MS in Computer Science, and an MBA from Stanford University.
David Sharp, Ph.D.
Co-Founder and Chief Science Officer
Dr. Sharp is is Professor of Physiology and Biophysics, Ophthalmology and Visual Sciences, and Neuroscience at the Albert Einstein College of Medicine in New York City. He is recognized as one of the world’s foremost experts on microtubules and cell movement, with numerous publications in prestigious journals including Cell, Nature, Nature Cell Biology, and Proceeding of the National Academy of Sciences.
His career-long research focus has been on the roles and regulation of the microtubule cytoskeleton in cell migration, division, and morphogenesis, as well as harnessing these mechanisms for tissue repair. He has co-authored over 60 papers on this topic to date and has received multiple research grants from federal and state government agencies and private foundations. Dr. Sharp’s research has led to the identification of enzymes that can be targeted in vivo to predictably alter cellular motility in a variety of clinical contexts related to tissue repair and regeneration, for which he has been issued seven U.S. patents. He is now leading the therapeutic translation of these findings for MicroCures.
Dr. Sharp has been the recipient of numerous research awards from the National Institutes of Health and the Department of Defense. He also has received the LaDonne H. Schulman Excellence in Teaching Award and is a scholar of the Leukemia and Lymphoma Society. Dr. Sharp holds a bachelor’s degree in psychology and a Ph.D. in neuroscience at the University of Wisconsin.
Peter Johnson, M.D.
Chief Medical Officer
Dr. Peter Johnson, a general and plastic surgeon, practiced reconstructive surgery for ten years at the University of Pittsburgh, where he founded and was the first President of the Pittsburgh Tissue Engineering Initiative. Subsequent roles included: co-founder and CEO of Tissue Informatics; EVP of Life Sciences, CMO and CBO of Icoria; EVP of Entegrion, Inc.; VP, R&D and Medical and Scientific affairs of Vancive Medical Technologies, an Avery Dennison business.
In addition to his work with MicroCures, Dr. Johnson also serves as President and CEO of Scintellix, LLC and co-founding Principal of MedSurgPI, LLC, and CEO of Beacon Biotherapeutics. He has chaired the Plastic Surgery Research Council and has been the President of the Pennsylvania Biotechnology Association and the Tissue Engineering Society, International (now TERMIS).
He serves on the board of the Transverse Myelitis Association, the Industrial Advisory Board of the UNC/NC State Joint Program in Bioengineering, the Industrial Technology Advisory Board of the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center, the board of the North Carolina Tissue Engineering and Regenerative Medicine Society, the board of Plakous Therapeutics, Inc., the board of Opsepio Therapeutics, Inc., the board of CellX Technology, and is Chairman of the Advisory Board for SonoVol, LLC.
He is an Adjunct Professor of Biomedical Engineering at the University of North Carolina at Chapel Hill, of Biomedical Engineering at NC State University and Duke University, and of Regenerative Medicine at Wake Forest University School of Medicine. Dr. Johnson received his undergraduate degree from the University of Notre Dame and earned an M.D. from SUNY Upstate Medical University.